top of page


10551 A Phase I/Ib Study of Anti-CD47 Hu5F9-G4 (Magrolimab) in Combination with Olaparib in Patients with BRCA1/2-Mutant Tumors

This research study is studying a new type of cancer treatment. The treatment combines two drugs - Magrolimab: This is a drug that helps the immune system recognize and attack cancer cells. Olaparib: This is a drug that blocks the PARP enzyme, which helps cancer cells repair their DNA. By blocking PARP, olaparib can make cancer cells more likely to die. This study is testing this combination of drugs in patients with tumors that have mutations in the BRCA1 or BRCA2 genes. These genes are involved in DNA repair, so tumors with mutations in these genes are often more sensitive to drugs that block PARP.The trial is still in the early stages (Phase I/II), so the main goals are to find the safest dose of the drugs and to see if they are effective in treating cancer. If the trial is successful, it could lead to larger studies that test the drugs in more patients.

Early stages: Early phase (phases I and II) studies help researchers determine: Whether a new treatment is safe, what its side effects are and the best dose of the new treatment.

For more information about the trial, click the link below:


Clinical Trial Site: Einstein

To see all available clinical trials click here.

Recent Posts

See All


Phase 2 Trial of Voyager V1 (Vesicular Stomatitis Virus Expressing NIS and Human Interferon Beta, VV1), in Combination with Cemiplimab in patients with Hepatocellular Carcinoma, Non-Small Cell Lung Ca


An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of


A Phase 1b Open-Label Multicenter Study of OP-1250 in Combination With the CDK4/6 Inhibitor Ribociclib or With the PI3K Inhibitor Alpelisib in Adult Subjects With Advanced and/or Metastatic HR Positiv


bottom of page